These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 12827224

  • 1. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 2. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.
    Ann Intern Med; 1998 Jul 01; 129(1):1-8. PubMed ID: 9652994
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD, Kipshoven C, Cöster A, Umbach R.
    Osteoporos Int; 1999 Jul 01; 9(2):171-8. PubMed ID: 10367046
    [Abstract] [Full Text] [Related]

  • 6. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P, Riis BJ, Christiansen C.
    J Clin Endocrinol Metab; 1999 Sep 01; 84(9):3013-20. PubMed ID: 10487657
    [Abstract] [Full Text] [Related]

  • 7. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar 01; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 8. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.
    Osteoporos Int; 2003 Oct 01; 14(10):793-800. PubMed ID: 12955333
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A, Adachi JD.
    Drug Saf; 2005 Oct 01; 28(8):721-30. PubMed ID: 16048357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.